BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23667632)

  • 1. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
    Gramatzki D; Herrmann C; Happold C; Becker KA; Gulbins E; Weller M; Tabatabai G
    PLoS One; 2013; 8(5):e63527. PubMed ID: 23667632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
    Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
    Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
    Ohba S; Hirose Y; Kawase T; Sano H
    J Neurooncol; 2009 Dec; 95(3):307-316. PubMed ID: 19517066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel.
    Giussani P; Bassi R; Anelli V; Brioschi L; De Zen F; Riccitelli E; Caroli M; Campanella R; Gaini SM; Viani P; Riboni L
    Cancer Invest; 2012 Jan; 30(1):27-37. PubMed ID: 22236187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
    Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW
    Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
    Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
    J Neurooncol; 2014 Aug; 119(1):91-100. PubMed ID: 24842385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
    Liu XY; Zhang L; Wu J; Zhou L; Ren YJ; Yang WQ; Ming ZJ; Chen B; Wang J; Zhang Y; Yang JM
    PLoS One; 2013; 8(11):e81345. PubMed ID: 24303044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
    Narayan RS; Fedrigo CA; Brands E; Dik R; Stalpers LJ; Baumert BG; Slotman BJ; Westerman BA; Peters GJ; Sminia P
    BMC Cancer; 2017 Mar; 17(1):204. PubMed ID: 28320338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
    Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC
    Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
    Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
    Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
    Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
    PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
    Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
    Köritzer J; Boxhammer V; Schäfer A; Shimizu T; Klämpfl TG; Li YF; Welz C; Schwenk-Zieger S; Morfill GE; Zimmermann JL; Schlegel J
    PLoS One; 2013; 8(5):e64498. PubMed ID: 23704990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
    Chen CC; Taniguchi T; D'Andrea A
    J Mol Med (Berl); 2007 May; 85(5):497-509. PubMed ID: 17221219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
    Kushal S; Wang W; Vaikari VP; Kota R; Chen K; Yeh TS; Jhaveri N; Groshen SL; Olenyuk BZ; Chen TC; Hofman FM; Shih JC
    Oncotarget; 2016 Mar; 7(12):13842-53. PubMed ID: 26871599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.